134 related articles for article (PubMed ID: 36528707)
1. Factors associated with prescription drug monitoring program utilisation: a cross-sectional survey of community pharmacists.
Picco L; Lam T; Xia T; Nielsen S
Int J Clin Pharm; 2023 Apr; 45(2):421-429. PubMed ID: 36528707
[TBL] [Abstract][Full Text] [Related]
2. Changes in opioid and other analgesic prescribing following voluntary and mandatory prescription drug monitoring program implementation: A time series analysis of early outcomes.
Nielsen S; Picco L; Russell G; Pearce C; Andrew NE; Lubman DI; Bell JS; Buchbinder R; Xia T
Int J Drug Policy; 2023 Jul; 117():104053. PubMed ID: 37209441
[TBL] [Abstract][Full Text] [Related]
3. How do patient, pharmacist and medication characteristics and prescription drug monitoring program alerts influence pharmacists' decisions to dispense opioids? A randomised controlled factorial experiment.
Picco L; Sanfilippo P; Xia T; Lam T; Nielsen S
Int J Drug Policy; 2022 Nov; 109():103856. PubMed ID: 36150356
[TBL] [Abstract][Full Text] [Related]
4. Utilization of prescription drug monitoring programs for prescribing and dispensing decisions: Results from a multi-site qualitative study.
Freeman PR; Curran GM; Drummond KL; Martin BC; Teeter BS; Bradley K; Schoenberg N; Edlund MJ
Res Social Adm Pharm; 2019 Jun; 15(6):754-760. PubMed ID: 30243575
[TBL] [Abstract][Full Text] [Related]
5. Mapping prescription drug monitoring program data to self-report measures of non-medical prescription opioid use in community pharmacy settings.
Charron E; Brooks JH; Peterson KT; Akinwolere OG; Winhusen T; Cochran G
Res Social Adm Pharm; 2023 Aug; 19(8):1171-1177. PubMed ID: 37142474
[TBL] [Abstract][Full Text] [Related]
6. Prescription drug monitoring programs in community pharmacy: An exploration of pharmacist time requirements and labor cost.
Upton C; Gernant SA; Rickles NM
J Am Pharm Assoc (2003); 2020; 60(6):943-950. PubMed ID: 32792293
[TBL] [Abstract][Full Text] [Related]
7. Pharmacists' training, perceived roles, and actions associated with dispensing controlled substance prescriptions.
Fleming ML; Barner JC; Brown CM; Shepherd MD; Strassels SA; Novak S
J Am Pharm Assoc (2003); 2014; 54(3):241-50. PubMed ID: 24816350
[TBL] [Abstract][Full Text] [Related]
8. Assessment of Postoperative Opioid Prescriptions Before and After Implementation of a Mandatory Prescription Drug Monitoring Program.
Shenoy R; Wagner Z; Kirkegaard A; Romanelli RJ; Mudiganti S; Mariano L; Martinez M; Zanocco K; Watkins KE
JAMA Health Forum; 2021 Oct; 2(10):e212924. PubMed ID: 35977161
[TBL] [Abstract][Full Text] [Related]
9. Educating Pharmacists on a Prescription Drug Monitoring Program.
Fleming ML; Phan Y; Ferries EA; Hatfield MD
J Pharm Pract; 2016 Dec; 29(6):543-548. PubMed ID: 25947949
[TBL] [Abstract][Full Text] [Related]
10. Association of state-level prescription drug monitoring program implementation with opioid prescribing transitions in primary care in Australia.
Xia T; Picco L; Buchbinder R; Haas R; Nielsen S
Br J Clin Pharmacol; 2024 Apr; 90(4):1162-1172. PubMed ID: 38308463
[TBL] [Abstract][Full Text] [Related]
11. Prescription drug monitoring program use and utility by Washington State pharmacists: A mixed-methods study.
Pett RG; Mancl L; Revere D; Stergachis A
J Am Pharm Assoc (2003); 2020; 60(1):57-65. PubMed ID: 31753615
[TBL] [Abstract][Full Text] [Related]
12. Stocking and supplying naloxone: Findings from a representative sample of community pharmacies in Victoria, Australia.
Karthikeyan N; Xia T; Nielsen S; Picco L
Drug Alcohol Rev; 2024 Jul; 43(5):1305-1312. PubMed ID: 38691509
[TBL] [Abstract][Full Text] [Related]
13. Changes in opioid agonist treatment initiation among people prescribed opioids for pain following voluntary and mandatory prescription drug monitoring program implementation: A time series analysis.
Picco L; Xia T; Bell JS; Pearce C; Buchbinder R; Lubman DI; Nielsen S
Drug Alcohol Rev; 2023 Nov; 42(7):1639-1646. PubMed ID: 37798947
[TBL] [Abstract][Full Text] [Related]
14. Attitudes of Florida pharmacists toward implementing a state prescription drug monitoring program for controlled substances.
Fass JA; Hardigan PC
J Manag Care Pharm; 2011; 17(6):430-8. PubMed ID: 21787028
[TBL] [Abstract][Full Text] [Related]
15. Physician attitudes and experiences with Maryland's prescription drug monitoring program (PDMP).
Lin DH; Lucas E; Murimi IB; Jackson K; Baier M; Frattaroli S; Gielen AC; Moyo P; Simoni-Wastila L; Alexander GC
Addiction; 2017 Feb; 112(2):311-319. PubMed ID: 27658522
[TBL] [Abstract][Full Text] [Related]
16. Association of the Use of a Mandatory Prescription Drug Monitoring Program With Prescribing Practices for Patients Undergoing Elective Surgery.
Stucke RS; Kelly JL; Mathis KA; Hill MV; Barth RJ
JAMA Surg; 2018 Dec; 153(12):1105-1110. PubMed ID: 30140927
[TBL] [Abstract][Full Text] [Related]
17. Trends in Florida's Prescription Drug Monitoring Program registration and utilization: Implications for increasing voluntary use.
Delcher C; Wang Y; Young HW; Goldberger BA; Schmidt S; Reisfield GM
J Opioid Manag; 2017; 13(5):283-289. PubMed ID: 29199394
[TBL] [Abstract][Full Text] [Related]
18. Clinical decision making involving prescription drug monitoring programs: A factorial, vignette-based study among student pharmacists.
Tata V; Varisco TJ; Du N; Nguyen J; Haghparast P; Thornton JD
J Am Pharm Assoc (2003); 2021; 61(3):316-324. PubMed ID: 33579594
[TBL] [Abstract][Full Text] [Related]
19. Impacts of prescription drug monitoring program policy changes and county opioid safety coalitions on prescribing and overdose outcomes in California, 2015-2018.
Henry SG; Shev AB; Crow D; Stewart SL; Wintemute GJ; Fenlon C; Wirtz SJ
Prev Med; 2021 Dec; 153():106861. PubMed ID: 34687731
[TBL] [Abstract][Full Text] [Related]
20. Accuracy and validity of reported opioid prescription days' supply.
Miracle DK; Slavova S; Brown JR; Dasgupta N; Harris S; Freeman PR
Pharmacoepidemiol Drug Saf; 2022 Dec; 31(12):1253-1261. PubMed ID: 36053913
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
